Despite the high long-term survival in localized prostate cancer, metastatic prostate cancer
remains largely incurable even after intensive multimodal therapy. The lethality of advanced …

Therapeutic advances in oncology have not fully translated to the treatment of metastatic
disease, which remains largely incurable. Metastatic subclones can emerge both early and …

The determination of molecular features that mediate clinically aggressive phenotypes in
prostate cancer remains a major biological and clinical challenge,. Recent advances in …

We integrated the genomic sequencing of 1,918 breast cancers, including 1,501 hormone
receptor-positive tumors, with detailed clinical information and treatment outcomes. In 692 …

Many primary-tumor subregions have low levels of molecular oxygen, termed hypoxia.
Hypoxic tumors are at elevated risk for local failure and distant metastasis, but the molecular …

Prostate cancer is the second most common cancer in men worldwide. Over the past
decade, large-scale integrative genomics efforts have enhanced our understanding of this …

Comprehensive genomic characterization of prostate cancer has identified recurrent
alterations in genes involved in androgen signaling, DNA repair, and PI3K signaling, among …

Ploidy abnormalities are a hallmark of cancer, but their impact on the evolution and
outcomes of cancers is unknown. Here, we identified whole-genome doubling (WGD) in the …

Precision medicine is an approach that takes into account the influence of individuals'
genes, environment, and lifestyle exposures to tailor interventions. Here, we describe the …

There is substantial heterogeneity among primary prostate cancers, evident in the spectrum
of molecular abnormalities and its variable clinical course. As part of The Cancer Genome …